Press "Enter" to skip to content

Health groups ask India to rescind Gilead’s patents for COVID-19 drug remdesivir

Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical drugs to them. Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.

Original source: https://health.economictimes.indiatimes.com/news/pharma/75736302?utm_source=RSS&utm_medium=ETRSS

Also Read:   7 Indian pharma cos face lawsuits from over 40 US states